Sol-gel reports first quarter 2024 financial results and provides corporate updates

Phase 3 clinical trial of sgt-610 for gorlin syndrome with the first patient screened, is ongoing. sol-gel and beimei pharma announced an asset purchase agreement to commercialize twyneo® in china, hong kong, macau, taiwan and israel, for a total consideration of up to $115 million.
SLGL Ratings Summary
SLGL Quant Ranking